Clinical trial
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced…
NCT00369070 · Amgen, Industry · Terminated
Key facts
| NCT number | NCT00369070 |
|---|---|
| Title | A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC |
| Official title | A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Non-squamous NSCLC |
| Intervention type | Biological, Drug |
| Interventions | Bevacizumab, AMG 706, Paclitaxel, Carboplatin |
| Enrollment | 186 |
| Start date | Jan 31, 2007 |
| Primary completion | Apr 23, 2008 |
| Completion | Aug 3, 2011 |
| First posted | Aug 29, 2006 |
| Last update posted | Jan 4, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: